Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tg Therapeutics (NQ: TGTX )

23.71 +0.40 (+1.72%)
Streaming Delayed Price Updated: 11:25 AM EDT, Oct 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 776,626
Open 23.06
Bid (Size) 23.70 (1)
Ask (Size) 23.72 (9)
Prev. Close 23.31
Today's Range 22.85 - 23.75
52wk Range 6.520 - 26.41
Shares Outstanding 154,420,772
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Delving into NASDAQ:TGTX's Growth Prospects.
Why TG THERAPEUTICS INC (NASDAQ:TGTX) qualifies as a high growth stock. 
Via Chartmill
NASDAQ:TGTX—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
TG THERAPEUTICS INC (NASDAQ:TGTX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill

Performance

YTD
+39.14%
+39.14%
1 Month
-3.81%
-3.81%
3 Month
+16.00%
+16.00%
6 Month
+68.16%
+68.16%
1 Year
+254.41%
+254.41%

More News

Read More
Why NASDAQ:TGTX qualifies as a high growth stock.
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:TGTX is worth considering.
Via Chartmill
Unlocking the Growth Potential of NASDAQ:TGTX.
Via Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Evaluating TG Therapeutics: Insights From 4 Financial Analysts
Via Benzinga
What's Going On With TG Therapeutics Stock Wednesday?
Via Benzinga
Why NASDAQ:TGTX is Poised for High Growth.
Via Chartmill
Stock Market Hits Record Highs On Big Fed Rate Cut; Apple, Intel, FedEx In Focus: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
IBD 50's TG Therapeutics Surges On Five-Year Data For Multiple Sclerosis Drug
Via Investor's Business Daily
Despite its growth, NASDAQ:TGTX remains within the realm of affordability.
Via Chartmill
NASDAQ:TGTX—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via Chartmill
What's Going On With ADMA Biologics Stock Monday?
Via Benzinga
Topics Stocks
Exposures US Equities
In the world of growth stocks, NASDAQ:TGTX shines as a value proposition.
Via Chartmill
Decoding TG Therapeutics's Options Activity: What's the Big Picture?
Via Benzinga
Why the growth investor may take a look at NASDAQ:TGTX.
Via Chartmill
A Closer Look at TG Therapeutics's Options Market Dynamics
Via Benzinga
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter
Via Investor's Business Daily
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
NASDAQ:TGTX: a strong growth stock preparing for the next leg up?.
Via Chartmill
NASDAQ:TGTX is showing decent growth, but is still valued reasonably.
Via Chartmill
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
Via Investor's Business Daily
S&P 500 Surges Over 2%; Caterpillar Earnings Beat Estimates
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.